How Novartis’s Tasigna Is Looking Now
Tasigna revenue trends
In 3Q17, Novartis’s (NVS) Tasigna reported revenues of $482 million, which was ~9% higher YoY (year-over-year) and 4% higher QoQ (quarter-over-quarter). Sales growth in the US and emerging markets primarily attributed to the revenue growth of Novartis in 3Q17.
Interested in VYMI? Don't miss the next report.
Receive e-mail alerts for new research on VYMI
ENTESTfreedom and ENTESTop trials
In June 2017, Novartis presented the results from the additional analysis of its phase-3 ENESTfreedom and ENESTop trials. The phase-3 ENESTfreedom and ENESTop trial demonstrated that around half of adult individuals with Philadelphia chromosome-positive chronic myeloid leukemia (or CML) in the chronic phase who discontinued Tasigna remained in treatment-free remission (or TFR) for approximately two years after stopping therapy.
The ENTESTfreedom trial evaluated the potential of discontinuation of Tasigna therapy in eligible candidates with Philadelphia chromosome-positive chronic myeloid leukemia (or CML) who achieved a sustained deep molecular response (or DMR) after a minimum of three years of first-line Tasigna therapy.
In the marketplace, Novartis Tasigna competes with Bristol-Myers Squibb’s (BMY) Sprycel, Pfizer’s (PFE) Bosulif, and Takeda Pharmaceuticals’ (TKPYY) Iclusig. In 3Q17, Sprycel reported revenues of ~$509 million. The Vanguard International High Dividend Yield ETF (VYMI) has ~1.18% of its total portfolio holdings in NVS.